One of the new, promising candidates for bacterium-mediated cancer therapy is the Escherichia coli Nissle 1917 (EcN) strain, which has probiotic properties. This strain was isolated by Alfred Nissle in 1917 from a German soldier who remained healthy while his comrades succumbed to infections caused by Shigella [ 13 ]. Purpose: SYNB1891 is a live, modified strain of the probiotic Escherichia coli Nissle 1917 (EcN) engineered to produce cyclic dinucleotides under hypoxia, leading to STimulator of INterferon Genes (STING) activation in phagocytic antigen-presenting cells in tumors and activating complementary innate immune pathways. The probiotic Escherichia coli strain Nissle 1917 is in addition to some Lactobacilli sp. one of the best-studied probiotic strains. This particular E. coli strain was isolated in 1917 based on its potential to protect from presumably infectious gastroenteritis. Initial therapeutic success was noted in the management of gastrointestinal The E. coli Nissle 1917 strain containing envZP41L also became more resistant to bile salts and colicin V and grew 50% slower in vitro in mucus and 15% to 30% slower on several sugars present in mucus, yet it was a 10-fold better colonizer than E. coli Nissle 1917. Here, a nonpathogenic probiotic, E. coli strain Nissle 1917 (EcN), was metabolically engineered to carry multiple copies of the 19-kb kps locus and produce heparosan to 9.1 g/L in fed-batch fermentation. Chromosome evolution driven by antibiotics was employed to amplify the kps locus, which governed the synthesis and export of heparosan from Studies have shown that EcN may be therapeutically effective in a variety of conditions such as ulcerative colitis, diarrhoea and chronic constipation. The E. coli strain Nissle 1917 is characterised by a number of features that set it aside from the rest of its family members. As a potent probiotic, it can work to promote digestive health. 66yc. Here we analyzed the impact of the gut microbiome on tumor colonization and tumor therapy by the Escherichia coli Nissle 1917 (EcN) strain. This EcN strain is a promising cancer therapy candidate with probiotic properties. Some researchers have designed and constructed an engineered probiotic based on E. coli Nissle 1917, which can specifically target and kill the two most common vancomycin-resistant Enterococcus, and significantly reduce the number of Enterococcus faecalis and Enterococcus faecium in the feces of model mice . Here, we investigated whether the probiotic Escherichia coli strain Nissle 1917 (ECN) could modulate the outcome of experimental autoimmune encephalomyelitis (EAE), a murine model of MS. We evidenced that daily oral treatment with ECN, but not with the archetypal K12 E. coli strain MG1655, reduced the severity of EAE induced by immunization Non-pathogenic bacteria with long historical use as probiotics and established safety profiles in humans, such as Escherichia coli Nissle 1917 (EcN) or Symbioflor-2, represent more favorable Evaluation of the effects of E. coli Nissle 1917 in the LPS-induced model of septic shock in mice. The mice were randomly assigned to three groups (n= 10); two of them (healthy and control groups) received tap water and the other (treated group) received the probiotic strain suspended in drinking water at the final concentration of 10 8 CFU·mL −1, prepared daily. Omega-3 fatty acids, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have beneficial effects on human health. The probiotic bacterium Escherichia coli Nissle is unable to produce either EPA or DHA. Escherichia coli Nissle was transformed with the pfBS-PS plasmid carrying the EPA/DHA gene cluster, previously isolated from a

e coli nissle 1917 probiotic